BREAKING: HHS Secretary-Designate Becerra Pledges to “Build On” 340B Contract Pharmacy Advisory Opinion

HHS Secretary-designate Xavier Becerra called 340B "an indispensable program" during a courtesy hearing before the Senate HELP Committee today.

President Biden’s pick to serve as U.S. Health and Human Services (HHS) secretary expressed his support for the recent HHS advisory opinion on contract pharmacy during questions today before a key congressional committee.

California Attorney General Xavier

Read More »

HHS-Designate Becerra May Face 340B Questions Today During First Nomination Hearing

HHS-Secretary designate Xavier Becerra could face questions about the 340B program today during his first of two Senate nomination hearings this week.

The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee this morning is holding the first of two Senate committee hearings this week on President Biden’s nomination of California Attorney General Xavier Becerra to serve as U.S. Health and Human

Read More »

Biden Staffs Up with 340B Policy Experts in Key Positions

President Biden is bringing a number of 340B policy experts on board to his team. Yesterday, he formally nominated Andrea Palm, most recently Wisconsin’s health secretary-designate, to be U.S. Deputy Secretary of Health and Human Services (HHS). Palm would be

Read More »

Ex-Energy & Commerce GOP Chair Walden Launches Lobbying Firm

Former House E&C GOP Chair Greg Walden (Ore.) has set up a public policy and political strategy firm in partnership with one of Washington’s top lobbying firms. | C-SPAN

Greg Walden (Ore.), the former Republican chair of the U.S. House Energy and Commerce (E&C) Committee, yesterday launched his own public policy and political strategy firm in partnership with one of Washington’s top lobbying firms.

Walden and the Alpine Group

Read More »

HRSA Allows 340B Enrollment Flexibility in Storm-Battered Texas

A Feb. 13-17 winter storm caused mass power outages and water and food shortages in Texas.

The U.S. Health Resources and Services Administration (HRSA), in light of the declared public health emergency in Texas, is letting eligible health care providers there enroll immediately in the 340B drug pricing program instead of waiting for the next normal

Read More »

AEH Asks Biden to Prioritize Three 340B-Related Issues

America's Essential Hospitals wants the Biden administration to reverse Trump administration policies that its says harm and the 340B program and are contrary to congressional intent. | Facebook

The Biden administration should reverse “harmful Trump administration policies” that “undermined the 340B program and contravened Congress’ intent,” the group America’s Essential Hospitals advised President Biden in a letter earlier this month.

America’s Essential Hospitals’ Feb. 10 letter said

Read More »

Biden Will Turn to Drug Pricing Once COVID-19 Ebbs, Shalala Predicts

Former HHS Secretary Donna Shalala (right) holds her rescue dog, Fauci, at the end of her talk yesterday during the 340B Coalition winter conference.

President Biden will likely turn to lowering drug prices once the COVID-19 pandemic stops demanding so much of his attention, Donna Shalala, U.S. Health and Human Services (HHS) Secretary during both of President Clinton’s terms in office, predicted in a

Read More »

Federal Judge Dismisses Hospitals’ 340B Contract Pharmacy Lawsuit Against HHS

A federal district judge in Oakland, Calif., has dismissed the lawsuit by hospitals against the U.S. Health and Human Services (HHS) Department over HHS’s enforcement of its 340B contract pharmacy requirements for drug companies.

U.S. District Judge Yvonne Gonzalez Rogers

Read More »

DOJ Slams Lilly’s Arguments for Derailing 340B Dispute Resolution

The U.S. Justice Department (DOJ) on Tuesday asked a federal district judge in Indianapolis, in a strongly worded filing, to deny drug manufacturer Eli Lilly’s motion in late January to block the 340B program’s new administrative dispute resolution (ADR) process.

Read More »

CBO Says Lifting Medicaid Drug Rebate Cap Would Save $16 Billion

Eliminating the cap on rebates that drug manufacturers pay to Medicaid would save Medicaid about $16 billion over 10 years, the CBO estimates.

The U.S. Congressional Budget Office (CBO) estimates that eliminating the limit on rebates that drug manufacturers pay to Medicaid, now capped at 100 percent of a drug’s average manufacturer price (AMP), “would reduce direct spending in Medicaid by $15.9 billion

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report